RussianPatents.com

Method of treating non-alcoholic steatohepatitis with application of dalargin magnetophoresis. RU patent 2473325.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, gastroenterology. Method includes dietotherapy in accordance with diet No 5, exercise therapy. Additionally intake of low-mineralised carbonaceous chloride-hydrocarbonate-sulfate-sodium-calcium mineral water "Essentuki-Novaya" is realised. Water is taken in in dose 3.5 ml per 1 kg of patient's body weight, 3 times per day, 30-40 minutes before meal. Carbonaceous-hydrogen sulfide mineral baths with content of hydrogen sulfide 15-20 mg/l are carried out every second day. Baths are taken with water temperature 36-37°C. Course includes 8-10 procedures. Dalargin magnetophoresis on liver projection is performed daily. Pulsing travelling magnetic field from apparatus AMO-ATOS is used. Magnetophoresis is carried out with induction 45 mT, with modulation frequency 10 Hz for 15 minutes, course includes 10 procedures.

EFFECT: method reduces treatment terms and increases its efficiency due to normalisation of oxidative homeostasis, improvement of functional state of liver and lipid metabolism.

2 ex, 4 tbl

IPC classes for russian patent Method of treating non-alcoholic steatohepatitis with application of dalargin magnetophoresis. RU patent 2473325. (RU 2473325):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61N2/04 - using variable fields, e.g. low frequency or pulsating fields

A61K38/08 - Peptides having 5 to 11 amino acids

A61K35/08 - Mineral waters

A61H33/02 - Bathing devices for use with gas-containing liquid, or liquid in which gas is led or generated, e.g. carbon dioxide baths

Another patents in same IPC classes:

Agent normalising liver mitochondria / 2470655
Invention refers to medicine, more specifically pharmacology. Grape seed extract is presented as an agent normalising liver mitochondria.

Agent possessing antiarrhythmic and hepatoprotective properties / 2469720
Invention refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide of formula I: as an agent possessing antiarrhythmic and hepatoprotective properties. The invention also refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide for preparing pharmaceutical compositions.

Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition / 2468803
There are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method for prevention of microcirculatory disorders in human / 2471519
Invention refers to medicine, namely physiotherapy. A method involves exposure to magnetic field. A patient is placed in a water bath. The exposure covers an injured organ. Magnetic field induction is 10-50 mT, while its frequency is 100 Hz. A first procedure starts with the exposition of 20 minutes. The following sessions are increased by 5 minutes each to reach the 40-minute exposition. The procedures are performed daily or every second day. The therapeutic course is 10-20 procedures. The method provides higher preventive effectiveness ensured by normalising arteriole tone, increased body functional reserves, and reduced risk of developing locomotor and internal diseases, including hepatic, renal and spleen ones.

Method of preventing stressogenic disorders in people / 2469755
Method lies in simultaneous impact with constant and alternating magnetic field. Impact with constant magnetic field is performed with induction 40-45 mcT. Impact with alternating magnetic field is performed with induction 40-45 mcT and frequency 1000 Hz. Patient is placed on magnetic couch, which makes it possible to perform impact with magnetic fields on entire organism. First procedure is carried out with 15-20-minute exposure. The following sessions of impact are made 5 minutes longer until 30-minute exposure is achieved. Procedures are carried out daily or every second day. Course of treatment includes 10-20 procedures.

Method of treating vibration sickness associated with dyscirculatory encephalopathy and hypertension / 2466757
Method involves simultaneous exposure to fluctuating currents and variable magnetic field. The exposure involves variable magnetic field of the half-sinusoidal form. The exposure is generated by two field magnets of the diameter of 5 cm. The magnets are arranged on sinocarotid neck areas. The exposure has induction 35 mTl, frequency 50 Hz. A procedure length is 15 minutes. The therapeutic course is 10 days.

Method for therapautic exposure of transcranial magnetic stimulation in prosopalgias / 2462281
Invention refers to medicine, particularly neurology. Patient's extremity muscle are examined with manual-muscular testing which aims at founding weak muscles to be used as an indicator for prescribing adequate electromagnetic exposure. For this purpose, a coil pre-connected to a transcranial magnetic stimulation apparatus with the specified electromagnetic exposure frequency and current intensity at zero level is placed above a patient's parietal area. The electromagnetic exposure parameters are gradually changed increasingly to achieve the normotonic state of the found hypotonic muscles. Further, every 15-30 seconds the muscular tonus is controlled to the moment of weakening. A criterion of the electromagnetic exposure termination is weakening of the examined muscles.

Method of treating traumatic neuropathies / 2459642
Invention refers to medicine, particularly neurotraumatology. A method involves using pharmacological preparations and physiotherapeutic procedures. As pharmacological preparations, neuromedin, vitamins B1 B12, trental are administered. The physiotherapeutic procedures involve trasspinal exposure of the spinal cord and cerebrospinal roots at a level of the occurrence of the roots involved in injured nerve formation to pulse magnetic field. The exposure includes rhythmed pulses at frequency 3 Hz at intensity 1.5-2 T. Duration of a session is 5-7 minutes. The therapeutic course is 10-15 procedures.

Method of treating patients suffering coxarthrosis / 2457007
Invention refers to medicine, namely - to traumatology, orthopaedics, physiotherapy. A method involves introducing nonsteroid anti-inflammatory, analgesic agents, vitamins, conducting magnetic therapy and phonophoresis. The magnetic therapy is conducted by the rotating pulse magnetic field with using the magtenic therapy apparatus UMTI-3F. An injured hip joint is placed inside solenoids. Phonophoresis is conducted in 10-15 minutes after the magnetic therapy. At the first stage of the disease, the magnetic therapy is performed at frequency 100 Hz and magnetic induction 16 mT in the mode III for 10-15 minutes. Phonophoresis involves applications of 5% Nurofen gel on the involved hip joint at frequency 880 Hz and intensity 0.4-0.7 Wt/cm2. pulse mode - 4 ms, exposure length 5-6 minutes for each joint. At the second stage of the disease, the magnetic field covers at frequency 100 Hz and magnetic induction 32 mT in the mode IV for 10-15 minutes. Phonophoresis involves applications of 5% Nurofen gel on the involved hip joint at frequency 880 kHz and intensity 0.7-0.8 Wt/cm2, in the continuous mode; the exposure length is 8-10 minutes for each joint. The procedures are daily. The therapeutic course is 10-12 procedures.

Method of local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms / 2455037
Invention refers to medicine, namely gynaecology, venereology and immunology, and is applicable for local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms. For this purpose, with underlying drug-induced therapy, the immunomodulatory therapy is used from first day of therapy by magnetic laser exposure on a uterus neck. The uterus neck is exposed by a gynecologic speculum which is removed after the procedure is completed. The magnetic laser exposure immediately covers a cervical canal. That is ensured by using a low-intensity laser with variable pulse generation. The magnetic field intensity makes 1.25 T. Pulse train frequency per minute is 30. A pulse interval is 100 msec. Length of the exposure is 5 minutes. The therapeutic course is 10 procedures.

Method of treating skin diseases with using magnetic garnet ferrite films / 2447911
Invention refers to medicine and aims at magnetic therapy of skin diseases. An affected body area is exposed to low-intensity structured magnetic fields at magnetic induction within the range of 5 to 50 mT generated by a non-volatile magnetic domain emitter representing a thin magnetic transparent monocrystalline magnetic garnet ferrite films of the thickness of 3-15 mcm epitaxially grown on a non-magnetic polished transparent monocrystalline gallium gadolinium garnet (GGG) substrate (the underfilm thickness is min.1000 mcm) and spontaneously divided on domains. The domain width in such films technologically varies in a broad range within 10 to 110 mcm, while the magnetic saturation is 1000 to 10-15 Gs. The exposure is performed with the magnetic garnet ferrite film placed immediately on the involved skin area.

Method of treating visual nerve and retinal diseases / 2447864
Invention refers to medicine, namely ophthalmology, and may be used in treating visual nerve and retinal diseases as neuroprotective therapy. That is ensured by introducing Corthexin 3 drops in both nasal passages every 2 minutes with the patient being in prone position. That is followed by a session of transcranial magnetic therapy in a projection of an optic tract with the use of the AMO-ATOS apparatus with the headband adaptor covering the temporal and occipital region. The procedure is daily for 10 days.

Method of treating vaginal disbioses and vaginites in females suffering chronic salpingo-oophoritis / 2445135
Invention refers to medicine, namely gynaecology, physiotherapy. A method involves magnetic laser exposure. Said exposure is performed by a vaginal technique. That is ensured by using infrared light emitted diodes of power 60 mWt. The exposure is performed at frequency 1500 Hz, magnetic field intensity 30 mT. On the first day, duration of the procedure makes 5 minutes, on the following days - 10 minutes. Each procedure of the magnetic laser exposure is followed by vaginal introductions of silt sulphide mud tampons of temperature 22-24°C for 60 minutes. After the procedure, residual silt sulphide mud is removed by vaginal douching with mineral water. The procedures are once a day. The therapeutic course is 10 procedures.

Combined therapy of pancreatic cancer with use of antigen polypeptide and chemotherapeutic agent / 2472522
Group of inventions refers to medicine, namely the combined therapy of pancreatic cancer with the use of antigen peptides VEGFR2 inducing cytotoxic cells. There are also disclosed a method and an agent for potentiating a therapeutic effect of chemotherapeutic agents, such as gemcitabine, as well as the use for preparing the pharmaceutical composition for cancer therapy in a patient.